Acceleron Pharma to Present at the Cowen 27th Annual Health Care Conference.CAMBRIDGE, Mass. -- Acceleron Pharma, Inc., a biopharmaceutical company developing novel biotherapeutics, today announced that Steven Ertel, Vice President Business Development, will provide a corporate presentation at the Cowen and Company 27th Annual Health Care Conference on Thursday March 15, 2007 at 9:30 a.m. (EST EST electroshock therapy. EST abbr. electroshock therapy ). The conference will be held at the Boston Marriott Copley Place Hotel, Boston, MA. About Acceleron Pharma Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, fat and the vasculature vasculature /vas·cu·la·ture/ (vas´ku-lah-chur) 1. circulatory system. 2. any part of the circulatory system. vas·cu·la·ture n. to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron's scientific approach takes advantage of its unique insight on the regenerative powers of two protein families: the Growth and Differentiation Factor (GDF) and Bone Morphogenetic Protein Bone Morphogenetic Proteins (BMPs) are a group of growth factors and cytokines known for their ability to induce the formation of bone and cartilage. Types Originally, seven such proteins were discovered. (BMP (1) (BitMaP) Also known as a "bump" file, it is the native, bitmapped graphics format in Windows. A BMP can be saved in several color options: 1-, 4-, 8- and 24-bit color provide 2, 16, 256 and 16,000,000 colors respectively. BMP files use the .BMP or . ) families. The company's lead program is an anabolic anabolic pertaining to or arising from anabolism. anabolic steroid steroids with a tissue-building effect. Testosterone is an example of a natural anabolic steroid with the, sometimes undesirable, effect of causing masculinization. bone agent being developed to reverse bone loss in diseases such as osteoporosis and cancer. Additionally, the company is advancing several preclinical programs that increase muscle mass, control angiogenesis and inhibit fat accumulation. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company's internal GMP GMP (guanosine monophosphate): see guanine. manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron are Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock Associates. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion